Hepatitis C virus infection in Western Europe
References (32)
- et al.
Prevalence, risk factors, and genotype distribution of hepatitis C virus infection in the general population: a community-based survey in southern Italy
Hepatology
(1997) - et al.
HCV genotypes in Northern Italy: a survey of 1368 histologically proven chronic hepatitis C patients
J Hepatol
(1998) - et al.
A twelve year natural history of hepatitis C virus infection in hemodialyzed patients
Kidney Int
(1994) - et al.
Infectivity of blood seropositive for hepatitis C virus antibodies
Lancet
(1990) Hepatitis C virus and hepatocellular carcinoma in developing and developed countries
Viral Hepatitis
(1998)Weekly Epidemiological Record
(1997)Guidelines for control and management of hepatitis C
(March 1998)- et al.
Epidemiology of hepatitis C virus infection in an area of Southern Italy
J Hepatol
(1997) Epidemiology of hepatitis C
Hepatology
(1997)- et al.
Hepatitis C
Risk factors of HCV infection among Elisa-positive blood donors according to RIBA-2 status: a case-control survey
Hepatology
Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection
N Engl J Med
Risk factors for the transmission of hepatitis C
J Hepatol
Viral hepatitis among injection drug users
Viral Hepatitis
Prevalence and incidence of hepatitis C virus among young adult injection drug users
J Acq Immune Defic Syndr Hum Retrovirol
Cited by (102)
Early virological assessment during telaprevir- or boceprevir-based triple therapy in hepatitis C cirrhotic patients who failed a previous interferon based regimen - The ANRS CO20-CUPIC study
2015, Clinics and Research in Hepatology and GastroenterologyCitation Excerpt :About 130–170 million people are chronically infected with the hepatitis C virus (HCV) worldwide[1], with 9 million infected in the United States and Western Europe [2,3].
Preparation of genosensor for detection of specific DNA sequence of the hepatitis B virus
2014, Applied Surface ScienceExamination of the risk of reinfection with hepatitis C among injecting drug users who have been tested in Glasgow
2012, International Journal of Drug PolicyCitation Excerpt :Approximately 26% of persons with acute HCV infection are able to spontaneously clear the virus (Micallef, Kaldor, & Dore, 2006) and the remainder become chronically infected, with the consequent risk of HCV-related disease progression: liver fibrosis, cirrhosis and hepatocellular carcinoma. For IDUs, who represent the largest at-risk group in Australia, USA, UK and other Western European countries (Alter et al., 1999; Dore, MacDonald, Law, & Kaldor, 2003; Health Protection Agency, 2009; Trepo & Pradat, 1999), the majority of transmission occurs through the sharing of contaminated injecting equipment, and so there is much opportunity for reinfection among those IDUs who do not use clean needles/syringes on each injecting occasion. There is a lack of consistent evidence regarding the question of whether previous HCV infection confers partial immunity upon re-exposure, and so leads to a lower risk of re-infection compared with the risk of new infection (Corson, Greenhalgh, Palmateer, Weir, & Hutchinson, 2011; Currie et al., 2008; van de Laar et al., 2009); such a lower risk of reinfection was observed in three cohort studies (Farci et al., 1992; Grebely et al., 2006; Mehta et al., 2002).
Changes in the prevalence of hepatitis C virus genotype among Italian injection drug users-Relation to period of injection started
2009, Journal of Clinical Virology